Rivaroxaban

XARELTO

Factor Xa Inhibitor

NADAC/unit $0.9790

No Shortage Tier 1: 134.0% PA Req: 0.3% 17 Manufacturers 58 ANDAs

Rivaroxaban prevents blood clots by inhibiting factor Xa, prescribed for atrial fibrillation and venous thromboembolism.

vs. brand XARELTO: Generic saves up to 90% per unit

Covered Lives

Generic Manufacturers

AIPING PHARMACEUTICAL INCALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDAPOTEX INCASCENT PHARMACEUTICALS INCAUROBINDO PHARMA LTDBIOCON PHARMA LTDBRECKENRIDGE PHARMACEUTICAL INCDR REDDYS LABORATORIES LTDINVAGEN PHARMACEUTICALS INCJANSSEN PHARMACEUTICALS INCLUPIN LTDMACLEODS PHARMACEUTICALS LTDMSN LABORATORIES PRIVATE LTDREGCON HOLDINGS LLCSCIEGEN PHARMACEUTICALS INCSUNSHINE LAKE PHARMA CO LTDTARO PHARMACEUTICAL INDUSTRIES LTD

Explore in the Ecosystem

rxsaver.aiCompare prices for Rivaroxaban drfinder.aiFind doctors who prescribe Rivaroxaban rxpbm.aiPBM spread analysis for Rivaroxaban clinicalrx.aiClinical profile: Rivaroxaban

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.